FDA approval expands range of Metadate (methylphenidate) dosages

Article

The Food and Drug Administration (FDA) this month approved the use of 40-mg, 50-mg, and 60-mg Medadate CD CII (methylphenidate HCI, manufactured by UCB) Extended-Release Capsules for the treatment of attention deficit hyperactivity disorder (ADHD).

The Food and Drug Administration (FDA) this month approved the use of 40-mg, 50-mg, and 60-mg Metadate CD CII (methylphenidate HCI, manufactured by UCB) Extended-Release Capsules for the treatment of attention deficit hyperactivity disorder (ADHD).

The capsules are already available in 10 mg, 20 mg, and 30 mg strengths, with a recommended starting dose of 20 mg once daily.

"The new strengths will allow for the full range of immediate-release doses (30% of the total) from a single capsule," said James M. Swanson, MD, PhD, professor of pediatrics at the University of California, Irvine. "The addition of these doses will allow physicians greater flexibility in tailoring a treatment regimen to the individual needs and responses of each patient."

Related Videos
Carissa Baker-Smith
Perry Roy, MD
Perry Roy, MD | Image Credit: Carolina Attention Specialists
Angela Nash, PhD, APRN, CPNP-PC, PMHS | Image credit: UTHealth Houston
Allison Scott, DNP, CPNP-PC, IBCLC
Joanne M. Howard, MSN, MA, RN, CPNP-PC, PMHS & Anne Craig, MSN, RN, CPNP-PC
Juanita Mora, MD
Natasha Hoyte, MPH, CPNP-PC
Lauren Flagg
© 2024 MJH Life Sciences

All rights reserved.